Jean-Pierre Sommadossi - 31 Jan 2023 Form 4 Insider Report for Atea Pharmaceuticals, Inc. (AVIR)

Role: President, CEO, and Chairman, Director
Signature: /s/ Andrea Corcoran, as Attorney-in-Fact for Jean-Pierre Sommadossi
Issuer symbol: AVIR
Transactions as of: 31 Jan 2023
Net transactions value: $0
Form type: 4
Filing time: 02 Feb 2023, 17:33:14 UTC
Previous filing: 02 Feb 2022
Next filing: 03 Mar 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AVIR	Restricted Stock Units	Award	$0	+520,400		$0.000000	520,400	31 Jan 2023	Common Stock	520,400		Direct	F1, F2
transaction	AVIR	Stock Option (Right to Buy)	Award	$0	+728,600		$0.000000	728,600	31 Jan 2023	Common Stock	728,600	$4.63	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2	The RSUs vest in three (3) equal annual installments on the first three anniversaries of the grant date such that the RSUs are fully vested on January 31, 2026.
F3	The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2023 such that the option is fully vested on January 31, 2027.